Corporate Presentation

NEO: AWKN

July 2021

Awakn™

Disclaimer

GENERAL DISCLAIMER

This presentation of Awakn Life Sciences Corp. (the "Company") is for information only and shall not constitute an offer to buy, sell, issue or subscribe for, or the solicitation of an offer to buy, sell or issue, or subscribe for any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The information contained herein is subject to change without notice and is based on publicly-available information, internally developed data, third party information and other sources. The third party information has not been independently verified. While the Company may not have verified the third party information, nevertheless, it believes that it obtained the information from reliable sources and has no reason to believe it is not accurate in all material respects. Where any opinion or belief is expressed in this presentation, it is based on the assumptions and limitations mentioned herein and is an expression of present opinion or belief only. No warranties or representations can be made as to the origin, validity, accuracy, completeness, currency or reliability of the information. The Company disclaims and excludes all liability (to the extent permitted by law), for losses, claims, damages, demands, costs and expenses of whatever nature arising in any way out of or in connection with the information in this presentation, its accuracy, completeness or by reason of reliance by any person on any of it. The information contained in this presentation does not purport to contain all the information that may be necessary or desirable to fully and accurately evaluate an investment in securities of the Company and is not to be considered as a recommendation by the Company that any person make an investment in the Company. The information in this presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. This presentation should not be construed as legal, financial or tax advice to any individual, as each individual's circumstances are different. Readers should consult with their own professional advisors regarding their particular circumstances.

Neither this presentation nor any copy of it may be taken or transmitted into or distributed in any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of applicable securities law. Recipients are required to inform themselves of, and comply with, all such restrictions or prohibitions and the Company does not accept liability to any person in relation thereto.

CAUTIONARY NOTE REGARDING FUTURE-ORIENTED FINANCIAL INFORMATION

To the extent any forward-looking statement in this presentation constitutes "future-oriented financial information" or "financial outlooks" within the meaning of applicable Canadian securities laws, such information is being provided to demonstrate the anticipated market penetration and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such future-oriented financial information and financial outlooks. Future-oriented financial information and financial outlooks, as with forward-looking statements generally, are, without limitation, based on the assumptions and subject to the risks set out below under the heading "Cautionary Note Regarding Forward Looking Information". The Company's actual financial position and results of operations may differ materially from management's current expectations and, as a result, the Company's revenue and expenses.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This presentation of the Company contains "forward-looking information", which may include, but is not limited to, statements with respect to anticipated business plans or strategies of the Company, the listing of Company's common shares on the NEO Exchange, the anticipated completion of clinical studies, the timing of any drug trials, the success of its pre-clinical and clinical trials, the ability to enter into acquisitions or collaborations to enhance its drug development platform, the success of any such acquisitions or collaborations and the ability to use the information relating to, or obtain patents or other intellectual property protection on, data and clinical trials generated directly by the Company or through such acquisitions or collaborations, the success or stage of development of discoveries or medicines, the progression of COVID-19 and its impacts on the Company's ability to operate its assets, including the possible shutdown of facilities due to COVID-19 outbreaks, the Company's ability to execute on the expansion of its digital platforms, risks associated with reliance on key personnel and risks associated with obtaining appropriate licensing. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "in ends", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to operate and expand the Company's facilities; engaging in activities which currently are illegal under Canadian or UK laws and the uncertainty of existing protection from UK, Canadian federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including federal and provincial legalization, due to inconsistent public opinion, perception of the use of psychedelic therapies, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; the Company's limited operating history and lack of historical profits; reliance on management; the Company's requirements for additional financing, and the effect of capital market conditions and other factors on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers. The foregoing factors are not intended to be exhaustive. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimate or intended.

Forward-looking statements contained herein are made as of the date of this presentation and the Company disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management's estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.

About Us

Awakn Life Sciences is a biotechnology company with clinical operations; researching, developing, and delivering psychedelic medicine to better treat Addiction.

Awakn's team consists of world leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat Addiction.

Awakn will also deliver evidence backed psychedelic therapies for Addiction in clinics in the UK and Europe and through licensing partnerships globally.

We are uniquely positioned to win a leadership role in the emerging psychedelic biotechnology industry because of our:

- Focus on better treating Addiction with psychedelics.
- Team, who are world leaders in psychedelic drug and therapy research.
- Strong drug and therapy development pipeline, specifically targeting Addiction.
- Clinics which will be the UK and EU's leading medical psychedelic therapy delivery platform.

Awakn's Focus and Objectives

Company Focus

We are a clinical stage biotechnology company with additional clinical operations developing psychedelic medicine to treat Addiction with two key focus areas:

Development

- Delivering the next generation of psychedelic drugs & therapies to treat Addiction.
- Developing enabling technologies to better treat Addiction.

Delivery

- Treating Addiction in a chain of medical psychedelic clinics and through licensing partnerships

Strategic Objectives

Development

- Be the leader in psychedelic drug and therapy research to treat Addiction.
- Be a leading developer of enabling technologies to treat Addiction.

Delivery

- Deliver psychedelic treatments for Addiction in a chain of Awakn owned clinics in the UK and EU.
- Scale our impact beyond the UK and EU through licensing partnerships.

Market Context

We are at a crisis point in the field of mental health provision and Addiction treatment.

20%

Mental health and addictions are the 5th leading cause of illness globally, affecting 20%[1] of the global population.

US$1.5trn

It costs the EU, US, and UK economies US$1.5trn in lost economic activity per annum[2].

US$31.5bn

The global substance Addiction treatment industry is valued at USD17.5bn per annum and is forecast to increase to USD31.5bn per annum by 2027[3].

US and EU

US accounts for 40% of this market, Europe 30%, Rest of World 20%[3].

Alcohol

Alcohol Use Disorder accounts for 30% of the treatment market.

Psychedelics have the potential to radically change Addiction treatment and deliver significantly better patient outcomes.

1. Global Burden of Disease, thelancet.com
2. OECD, oecd.org
3. Reports and Data, reportsanddata.com

Corporate Board

George Scorsis

CHAIR

George has 15 years experience leading companies in highly regulated industries to rapid growth, including alcohol, energy drinks and, most recently, medical cannabis.

Formerly President of Red Bull Canada, he was instrumental in restructuring the organisation and growing the business to $150 MM in revenue.

Anthony Tennyson

CHIEF EXECUTIVE OFFICER

Anthony is an experienced financial services industry executive with 10 years in international strategy, commercial leadership roles with Aon plc, and 5 years with Merrill Lynch and Bank of Ireland.

Anthony holds an MBA in Strategy and Finance and an MSc in Technology both from UCD, Ireland's top ranked business school.

Dr. Ben Sessa

CHIEF MEDICAL OFFICER

Ben has specialist training as a child and adolescent psychiatrist and is interested in the developmental trajectory from child maltreatment to adult mental health disorders, including adult addictions. Dr Sessa's joint interests in psychotherapy, pharmacology and trauma have led him towards researching the subject of drug-assisted psychotherapy using psychedelic adjuncts. In the last 15 years he has been part of scientific and clinical studies administering LSD, psilocybin, ketamine, MDMA and DMT to patients and volunteers.

He is the author of psychedelic medical exploration books; The Psychedelic Renaissance (2012 and 2017) and To Fathom Hell or Soar Angelic (2015). He has recently completed research with Imperial College London exploring the world's first MDMA-assisted therapy trial for the treatment of Alcohol Dependence Syndrome.

Alongside Prof. David Nutt, Ben has also been a long term advocate of drug policy reform in the UK; believing that current laws hamper research and increase, rather than reduce, the burden of problematic drug use on individuals and society.

Stephen Page

INDEPENDENT NON-EXECUTIVE DIRECTOR

Stephen Page has worked at Chief Executive and Board level in UK healthcare for over 30 year, most noticeably leading Priory Healthcare, the largest network of mental healthcare hospitals and clinics in the UK, through a period of rapid expansion and market dominance. He has led and successfully grown organisations in both public and private sectors including Oxleas NHS Trust in London, Nestor plc and Acorn Care and Education.

As founding CEO of Acorn Care and Education, and supported by Phoenix Equity Partners, Steve built the company via acquisition and organic growth to be a leading national provider of special needs education and foster care. He led the sale to the Ontario Teachers' Pension Plan in 2010.

Steve has a Business Studies Degree from Sheffield University and an MBA from London Business School

Prof. John Papastergiou

INDEPENDENT NON-EXECUTIVE DIRECTOR

Professor John Papastergiou is a highly regarded pharmacist and clinical research scientist who has served as an advisor to several leading pharmaceutical organisations including Bayer, Pfizer, GSK, and Astra Zeneca.

He holds faculty appointments at the schools of Pharmacy at both the University of Toronto and the University of Waterloo. In 2019, he was named by the International Forum on Advancement of Healthcare as one of the top 100 healthcare leaders globally and was also presented with the Ontario Pharmacists' Association Award for Excellence in Research and Academia.

Professor Papastergiou holds multiple degrees including a PhD from Radboud University, Netherlands; and is a sought-after author, media personality and speaker at international scientific conferences and events.

Leadership Team

Anthony Tennyson

CHIEF EXECUTIVE OFFICER

Anthony is an experienced financial services industry executive with 10 years in international strategy, commercial leadership roles with Aon plc, and 5 years with Merrill Lynch and Bank of Ireland.

Anthony holds an MBA in Strategy and Finance and an MSc in Technology both from UCD, Ireland's top ranked business school.

Jonathan Held

CHIEF FINANCIAL OFFICER

Jonathan is a chartered professional accountant, with CFO level experience for private / public companies.

Jonathan has worked in a number of sectors including technology, biotech and natural resources, both domestic and international, and has been involved in numerous successful public market transactions including Initial Public Offerings, Reverse Takeovers and financings.

James Collins

CHIEF OPERATING OFFICER

James is a senior business leader and mental health champion with 17 years of experience with Accenture Strategy, 7 years as MD, designing and delivering corporate, digital and operating model strategies.

James holds a BSc and MPhil in Psychology from University College London (UCL).

Dr. Ben Sessa

CHIEF MEDICAL OFFICER

Ben has specialist training as a child and adolescent psychiatrist and is interested in the developmental trajectory from child maltreatment to adult mental health disorders, including adult addictions. Dr Sessa's joint interests in psychotherapy, pharmacology and trauma have led him towards researching the subject of drug-assisted psychotherapy using psychedelic adjuncts. In the last 15 years he has been part of scientific and clinical studies administering LSD, psilocybin, ketamine, MDMA and DMT to patients and volunteers.

He is the author of psychedelic medical exploration books; The Psychedelic Renaissance (2012 and 2017) and To Fathom Hell or Soar Angelic (2015). He has recently completed research with Imperial College London exploring the world's first MDMA-assisted therapy trial for the treatment of Alcohol Dependence Syndrome.

Alongside Prof. David Nutt, Ben has also been a long term advocate of drug policy reform in the UK; believing that current laws hamper research and increase, rather than reduce, the burden of problematic drug use on individuals and society.

Dr. Laurie Higbed

LEAD PSYCHOLOGIST

Laurie is an experienced clinical psychologist. Laurie has worked as a lead therapist on clinical trials using MDMA and psilocybin-assisted psychotherapy and has a special interest in working with complex trauma, addictions and the use of psychedelic therapy to treat a range of mental health difficulties.

Laurie is registered with the Health and Care Professions Council (HCPC) and is a member of the Association of Clinical Psychologists (ACPUK).

Leadership Team

Prof. Celia Morgan

HEAD OF KETAMINE ASSISTED PSYCHOTHERAPY FOR ADDICTION

Celia is a Professor of Psychopharmacology at the University of Exeter in the United Kingdom.

Prof. Morgan completed her undergraduate degree and Ph.D at University College London (UCL) and completed a scholarship programme at Yale University. After competing her Ph.D Prof. Morgan worked at University of Melbourne as a visiting research fellow, returning to UCL for a fellowship and then Lectureship. She joined University of Exeter as a Senior Lecturer in 2013 and was given a Chair in Psychopharmacology in 2015.

Prof. Morgan also holds an Honorary Readership at University College London. Prof. Morgan is academic lead for both Exeter Translational Addiction Partnership (ETAP) and Ketamine for Reduction of Alcoholic Relapse (KARE).

Prof. David Nutt

CHIEF RESEARCH OFFICER

David is a psychiatrist and the Edmund J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science, Dept of Medicine, Imperial College London. Here he uses a range of brain imaging techniques to explore the causes of addiction and other psychiatric disorders and to search for new treatments. He has published over 400 original research papers, a similar number of reviews and books chapters, eight government reports on drugs and 28 books, including one for the general public, Drugs: Without The Hot Air, that won the Transmission Prize in 2014.

He is currently the President of the European Brain Council and Founding Chair of Drug Science. Previously he has been president of the British Association of Psychopharmacology, the British Neuroscience Association, and the European College of Neuropsychopharmacology. He broadcasts widely to the general public both on radio and television. In 2010 The Times Eureka science magazine voted him one of the 100 most important figures in British Science, and the only psychiatrist in the list. In 2013 he was awarded the John Maddox Prize from Nature/Sense about Science for standing up for science.

Dr. Shaun McNulty

CHIEF SCIENTIFIC OFFICER

Shaun is an experienced CNS drug discovery expert and biotechnology executive. He has over 25 years of industry experience in the neuroscience drug discovery units of major pharmaceutical company, including Parke-Davis, Pfizer and GSK, in contract research for Charles River, and as CSO for several biotechnology companies. Shaun has worked to develop a range of CNS targeted drugs including Neurontin and Lyrica, specialising now in drug development strategy and the successful transfer of drug candidates into clinical trials.

Shaun holds a D.Phil. in CNS cell signalling from the University of York and researched neurotransmitter-regulated pathways controlling circadian function and behaviour at the University of Cambridge, UK.

Gordo Whittaker

HEAD OF MARKETING AND COMMUNICATIONS

Gordo is a senior marketing and communications leader with over 10 years' experience, building, protecting and growing some of the world's most famous brands, including Volkswagen and Land Rover, where he led their global advertising function.

Pre-Clinical Advisory Board

Prof. David Nutt

CHIEF RESEARCH OFFICER

David is a psychiatrist and the Edmund J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science, Dept of Medicine, Imperial College London. He has published over 400 original research papers, a similar number of reviews and books chapters, eight government reports on drugs and 28 books.

He is currently the President of the European Brain Council and Founding Chair of Drug Science. Previously he has been president of the British Association of Psychopharmacology, the British Neuroscience Association, and the European College of Neuropsychopharmacology.

Dr. Shaun McNulty

CHIEF SCIENTIFIC OFFICER

Shaun is an experienced CNS drug discovery expert and biotechnology executive. He has over 25 years of industry experience in the neuroscience drug discovery units of major pharmaceutical company, including Parke-Davis, Pfizer and GSK, in contract research for Charles River, and as CSO for several biotechnology companies. Shaun has worked to develop a range of CNS targeted drugs including Neurontin and Lyrica, specialising now in drug development strategy and the successful transfer of drug candidates into clinical trials.

Shaun holds a D.Phil. in CNS cell signalling from the University of York and researched neurotransmitter-regulated pathways controlling circadian function and behaviour at the University of Cambridge, UK.

Prof. Stephen Husbands

ADVISOR

Professor Husbands is professor of medicinal chemistry in Department of Pharmacy and Pharmacology at the University of Bath. His research has focused on the development and therapeutic potential of central nervous system targeted ligands, particularly those interacting with multiple receptors. His interests relate to neuropsychological diseases, in particular the development of low abuse liability analgesics and new treatment agents for drug abuse, depression and anxiety. He has more than 120 publications (including book chapters) and his work has been supported by national and international (NIH) funding agencies as well as industry. Prof Husbands' work is highly interdisciplinary, and he collaborates and publishes with researchers around the world.

Prof. Harriet de Wit

ADVISOR

Prof. de Wit obtained her PhD in Experimental Psychology from Concordia University in Montreal, Canada, in 1981. Since then she has been associated with the Department of Psychiatry and Behavioral Neuroscience at the University of Chicago, where she is currently Professor and Director of the Human Behavioral Pharmacology Laboratory. In addition to her role as Principal Investigator for several NIH-funded research projects, Dr. de Wit serves as Field Editor for the journal Psychopharmacology. She is a consultant to the Food and Drug Administration and serves on scientific advisory boards at other institutions. She has received awards for her research, including the Marian W. Fischman Memorial Lectureship Award in 2009, the European Behavioral Pharmacology Society Distinguished Investigator Award in 2019 and the Research Society on Alcoholism Lifetime Achievement Award in 2020.

Prof. Kevin Fone

ADVISOR

Professor Fone is the Professor of Neuroscience at the University of Nottingham. His research interests include improving our understanding of the neurobiological aetiology of common CNS disorders, such as schizophrenia, depression, PTSD and ADHD, and to help develop novel therapeutic treatment strategies for these. His research uses integrated physiology to investigate the functional role of 5-HT and dopamine in the CNS and to evaluate the impact of early-life interventions on brain development and behaviour. The fundamental approach is to concomitantly measure neurotransmitter function, neurochemistry and behaviour in paradigms designed to model CNS disorders. Kevin has benefited from extensive funding from Research Councils, EU consortiums, and many pharmaceutical companies from all over the world. He is a Fellow of the British Pharmacological Society, member of the scientific advisory board for the ECNP and has been President for both the International Society for Serotonin Research and the British Association for Psychopharmacology.

Clinical Advisory Board

Prof. David Nutt

CHIEF RESEARCH OFFICER

David is a psychiatrist and the Edmund J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science, Dept of Medicine, Imperial College London. He has published over 400 original research papers, a similar number of reviews and books chapters, eight government reports on drugs and 28 books.

He is currently the President of the European Brain Council and Founding Chair of Drug Science. Previously he has been president of the British Association of Psychopharmacology, the British Neuroscience Association, and the European College of Neuropsychopharmacology.

Dr. Ben Sessa

CHIEF MEDICAL OFFICER

Ben has specialist training as a child and adolescent psychiatrist and is interested in the developmental trajectory from child maltreatment to adult mental health disorders, including adult Addictions. Dr Sessa's joint interests in psychotherapy, pharmacology and trauma have led him towards researching the subject of drug-assisted psychotherapy using psychedelic adjuncts. In the last 15 years he has been part of scientific and clinical studies administering LSD, psilocybin, ketamine, MDMA and DMT to patients and volunteers.

Prof. Celia Morgan

HEAD OF KETAMINE ASSISTED PSYCHOTHERAPY FOR ADDICTION

Celia is a Professor of Psychopharmacology at the University of Exeter in the United Kingdom.

Prof. Morgan completed her undergraduate degree and Ph.D at University College London (UCL) . After her Ph.D Prof. Morgan worked at University of Melbourne as a visiting research fellow, returning to UCL for a fellowship and then Lectureship. She joined University of Exeter as a Senior Lecturer in 2013 and was given a Chair in Psychopharmacology in 2015.

Prof. Morgan also holds an Honorary Readership at University College London. Prof. Morgan is academic lead for both Exeter Translational Addiction Partnership (ETAP) and Ketamine for Reduction of Alcoholic Relapse (KARE).

Dr. Michael Mithoefer

ADVISOR

Michael Mithoefer, M.D., began collaborating with MAPS in 2000 on the first U.S. Phase 2 clinical trial of MDMA-assisted psychotherapy.

He has since conducted two of the six MAPS-sponsored Phase 2 clinical trials testing MDMA-Assisted Psychotherapy for PTSD, as well a study providing MDMA-assisted sessions for therapists who have completed the MAPS-sponsored MDMA Therapy Training Program, and a pilot study treating couples with MDMA-Assisted Psychotherapy combined with Cognitive-Behavioural Conjoint Therapy.

He is now Senior Medical Director for Medical Affairs, Training and Supervision at MAPS Public Benefit Corporation (MAPS PBC). He is a Grof-certified Holotropic Breathwork Facilitator, is trained in EMDR and Internal Family Systems Therapy, and has nearly 30 years of experience treating trauma patients.

Ann Mithoefer, BSN

ADVISOR

Ann Mithoefer, B.S.N., is a Registered Nurse focused primarily on training and supervising therapists conducting MAPS-sponsored clinical trials, as well as continuing to conduct some MAPS research sessions.

Between 2004 and 2018, she and her husband, Michael Mithoefer, M.D., completed two of the six MAPS-sponsored Phase II clinical trials testing MDMA-Assisted Psychotherapy for PTSD, as well a study providing MDMA-assisted sessions for therapists who have completed the MAPS Therapist Training, and a pilot study treating couples with MDMA-Assisted Psychotherapy combined with Cognitive-Behavioural Conjoint Therapy.

Ann is a Grof-certified Holotropic Breathwork Practitioner, is trained in Hakomi Therapy, and has 25 years' experience working with trauma patients, with an emphasis on experiential approaches to psychotherapy.

Clinical Advisory Board

Prof. Matthew W. Johnson

ADVISOR

Prof. Matthew W. Johnson, Ph.D., is Professor of Psychiatry and Behavioral Sciences at Johns Hopkins. He is one of the world's most published scientists on the human effects of psychedelics, and has conducted seminal research in the behavioural economics of drug use, addiction, and risk behavior. Dr. Johnson earned his Ph.D. in experimental psychology at the University of Vermont in 2004.

Working with psychedelics since 2004, Dr. Johnson published psychedelic safety guidelines in 2008, helping to resurrect psychedelic research. As Principle Investigator he developed and published the first research on psychedelic treatment of tobacco addiction in 2014. Dr. Johnson and colleagues published the largest study of psilocybin in treating cancer distress in 2016. His 2018 psilocybin abuse liability review recommended placement in Schedule-IV upon potential medical approval.

Barbara J. Mason

ADVISOR

Barbara J. Mason, Ph.D. is Director of the Pearson Center for Alcoholism and Addiction Research, Director of the Laboratory of Clinical Psychopharmacology, and Pearson Family Professor in the Department of Molecular Medicine at The Scripps Research Institute, La Jolla, CA. Dr. Mason's work in medication development for the treatment of substance use disorder has been recognized globally. Prof. Mason conducted the seminal studies identifying nalmefene as having therapeutic potential for alcohol dependence; and also served as overall Principal Investigator for the US 21-center trial of acamprosate (Campral) for the treatment of alcohol dependence which was conducted in support of FDA approval. Prof. Mason has served on the National Advisory Councils of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the National Institute on Drug Abuse (NIDA). She has served as a guest expert for the U.S. Federal Food and Drug Administration (FDA) and as a reviewer of research grants for NIH and the Medical Research Council (MRC) of the UK.

Awakn Business Model

DEVELOPMENT

Research

Next generation psychedelic drugs to treat Addiction

MDMA for Alcohol Use Disorder

Ketamine for Addiction and AUD

Development

Enabling Technologies to improve the effectiveness of Psychedelics in treating Addiction.

DELIVERY

Clinics

Treat Addiction and other mental health conditions

Partnerships

Scale our impact and reach through licensing partnerships

Development: Research

Development: Research

Our research team consists of world leading experts in the fields of drug development, clinical research, psychiatry, and psychotherapy.

Our team, is building a pipeline of new therapies and drug candidates (designed to be used in conjunction with psychotherapy).

We will focus our research activities on treating addictions where the consequences for the patient, their family and society are at present most severe, with near, medium, and long-term programs.

NEAR TERM

Ketamine

Ketamine-Assisted Psychotherapy for Alcohol Use Disorder

MEDIUM TERM

MDMA

MDMA - Assisted Psychotherapy for Alcohol Use Disorder

LONG TERM

New Chemical Entities

Alcohol, behavioural, opioid, and tobacco addictions

Development: Research

Our drug and therapy development pipeline



Development: Research

Near Term: Ketamine for Reduction of Alcoholic Relapse (KARE) 2016 - 2020

Four armed Phase II for reducing relapse in alcohol use disorder with the NMDA Receptor Antagonist Ketamine.

Research team: Prof. Celia Morgan | N=96 | Published: June / July 2021

Research Question

Is ketamine effective (both with and without therapy) in promoting and prolonging abstinence in patients with alcohol use disorder following detox?

Ketamine
(IV 0.8 mg/kg) over 40 mins

- N = 24+ KARE Therapy
- N = 24+ Alcohol Education

Placebo
(IV saline) over 40 minutes

- N = 24+ KARE Therapy
- N = 24+ Alcohol Education

Awakn has acquired the proprietary therapy manual from this trial.

PI from trial, Prof Morgan, will oversee delivery of the KARE treatment in Awakn Clinics.

Awakn will be the only company in the world providing evidence backed ketamine-assisted psychotherapy for AUD.

Development: Research

Medium Term: MDMA: Phase IIb clinical trial to assess efficacy of MDMA-Assisted Therapy for Alcohol Use Disorder

A double-blind randomized controlled study to test the effectiveness of MDMA-assisted therapy for the treatment of patients with non-physically dependent ('Harmful Use') Alcohol Use Disorder, building on Dr. Ben Sessa's Phase IIa BIMA study published in February 2021 [1].

Coordinating Investigator: Prof. Nutt | Trial Stage = Ph IIb | Sponsor: Awakn | CRO: PRA Health Sciences | Competent Authority: MHRA

Stage 01

Primary Endpoint: Weekly units of alcohol consumed at 9 months (36 weeks) after the end of treatment, as measured using the alcohol Timeline Follow Back (TLFB) diary

Stage 02

MHRA

Scientific Advisory Meeting

Due in Q3 2021

Ethics Committee

Due in Q3 2021

Stage 03

First Time in Human

Due in Q4 2021

Stage 04

Data Readout

Due in 2023

Development: Research

Long Term: NCE drug development program targeting Addiction.

We are developing the next generation of patentable psychedelic medicines to treat Addiction.

Research team: Prof. David Nutt, Dr. Shaun McNulty, and Prof. Celia Morgan

Stage 01

6 years' of proprietary data and research acquired from Prof. David Nutt's Equasy Enterprises, including newly discovered actions of MDMA.

Acquired in Q2 2021

Stage 02



Intelligent/Computer aided design / validation of patentable candidate molecules

Started in Q2 2021

Stage 03



Characterisation of a candidate and back up for clinical development

Starting in 2022

Stage 04



CTA/IND enabling studies and process development to facilitate FTIH study

Starting in 2023

Development

Development

2021

Data Capture

General Data Protection Regulation (GDPR) and Privacy compliant data capture of touch points with participants in Awakn Research clinical trials and clients of Awakn Clinics.

Identity Transformation

Track identity transformation during psychological therapy using advanced data analytic techniques.

2022

Natural Language Processing

Treat Addiction and other mental health conditions

Predictive & Supportive Analytics

Develop and commercialise suite of predictive and support analytics to help support Psychedelic-Assisted Psychotherapy practitioners.

Delivery: Clinics

Delivery: Clinics

clinics.awaknlifesciences.com

Providing hope for those for whom the status quo is not working by combining the proven therapeutic potential of psychedelics with psychotherapy to treat Addiction and other mental health conditions.

Each Awakn Clinic will be owned and operated by Awakn, will be led by a consultant psychiatrist, will deliver ketamine-assisted psychotherapy in the near term, and will utilize MDMA when Awakn secures marketing authorization.

Some Awakn Clinics will also be sites for Awakn Research's clinical trials.

2021

United Kingdom

- Bristol
- London #1
- Manchester

2022

United Kingdom

- London #2
- Birmingham
- 3x clinics in UK

European Union

- Dublin, Ireland

2023+

European Union

- Scandinavia
- Benelux (Belgium, Netherland, Luxembourg)
- France
- Iberia (Spain and Portugal)
- DACH (Germany, Austria, Switzerland)
- Eastern Europe

Delivery: Clinics

clinics.awaknlifesciences.com

Our target is 20 clinics by end 2024.

Each clinic will generate between GBP£1.75m and GBP£3.5m revenue.

UK clinic opening lead time is 6 months, EU is 6 to 12 months depending on jurisdiction.

2021

Ketamine-Assisted Psychotherapy

Full therapeutic Psychedelic-Assisted Psychotherapy course focused on addressing a wide range of mental health issues with shorter follow on treatment courses also available.

Awakn will be the only company in the world providing Ketamine-Assisted Psychotherapy for Alcohol Use Disorder validated already in a Ph II clinical trial.

FUTURE

MDMA-Assisted Psychotherapy

MDMA-Assisted Psychotherapy when Awakn secures marketing authorization in the UK and EU.

Delivery:
Partnerships

Delivery: Partnerships

Scale our reach beyond our core territories through licencing to enable Addiction treatment practitioners deliver the Awakn methodology:

Protocols & Therapy Manuals

Access to Awakn proprietary ketamine and MDMA-Assisted Psychotherapy treatment protocols and therapy manuals.

Training

Certified training in delivery of proprietary ketamine and MDMA-Assisted Psychotherapy treatment protocols and therapies.

Clinic Best Practice

Evidence based clinical design best practices.

Data, Analytics, Insights

Predictive Analytics to improve the efficiency of Psychedelic-Assisted Psychotherapy.

Capital Structure

Trading Symbol **NEO: AWKN**

CAPITAL STRUCTURE

Common Shares	24,485,196
Warrants	1,984,868
Stock Options	1,585,000
Fully Diluted	28,055,064

No Debt	
Management / Insider Ownership	22.91%

Comparables

Market Capitalization as of 10th June 2021 [1]

	atai LIFE SCIENCES	COMPASS Navigating Mental Health Pathways	mindmed	PRIORY	field trip	MAPS MULTIDISCIPLINARY ASSOCIATION FOR PSYCHEDELIC STUDIES
OPERATIONAL FOCUS	Trials and Drug Dev.	Drug Dev., Trials, and Training	Trials and Drug Dev.	Clinics (Addiction & Mental Health)	Clinics	Trials and Training
MARKET SEGMENT	Medical	Medical	Medical	Medical	Medical	Medical
PUBLIC OR PRIVATE	Public	Public	Public	Public	Public	Public
MARKET CAPITALIZATION	CAD$3.7bn	CAD$2.1bn	CAD$2.1bn	CAD$1.8bn	CAD$407m	-

Source: Company reports, Thomson Eikon, SEDAR.

Why Invest in Awakn?

Clear IP development pathway
- Psychedelic drug discovery targeting Addiction
- Psychedelic therapy development targeting Addiction
- Enabling technologies & predictive analytics



Multiple revenue streams:
- Clinic revenue starting in 2021.
- Partnership Ecosystem revenue starting in 2022.
- Drug discovery revenue in 2028+

Unique focus on and first mover advantage in UK and EU: 400m population and US$20trn GDP.



Global research leaders in the field of psychedelic treatments for Addiction: Dr. Ben Sessa led the world's only MDMA-Assisted Psychotherapy and AUD study (BIMA) and Prof. Celia Morgan led the world's only Ketamine-Assisted Psychotherapy AUD study (KARE).

The leading scientific and medical team in the industry: Prof. David Nutt, Dr. Ben Sessa, Prof. Celia Morgan, Dr. Michael Mithoefer, Ann Mithoefer, and Prof. Matt Johnson.

Strategic partnerships with two leading UK universities for exclusive access to data and findings from recent clinics trials.

Enquiries

Anthony Tennyson, CEO

anthony@awaknlifesciences.com
+353 (0)87 103 6542

Investor Enquiries:

KCSA Strategic Communications

Valter Pinto / Tim Regan
Phone: +1 (212) 896-1254
Awakn@KCSA.com

Media Enquiries:

America and Canada:
KCSA Strategic Communications

Anne Donohoe
Adonohoe@KCSA.com

Rest of World:

ROAD Communications

Paul Jarman / Anna Ramsey
Awakn@roadcommunications.co.uk


Awakn™